Peptide based macrocycles: Selective histone deacetylase inhibitors with antiproliferative activity

Current Medicinal Chemistry

Volumn 20, Issue 14, 2013, Pages 1887-1903

  Rajak, H ^a   Singh, A ^a   Dewangan, P K ^a   Patel, V ^a   Jain, D K ^a   Tiwari, S K ^a   Veerasamy, R ^b   Sharma, P C ^c  

^a GURU GHASIDAS UNIVERSITY   (India)

^b AIMST UNIVERSITY   (Malaysia)

^c KURUKSHETRA UNIVERSITY   (India)

Author keywords

Anticancer agents; Apoptosis; Cyclic tetrapeptides; Depsipeptides; Extrinsic pathway; HDAC; Histone acetylation; Histone deacetylase inhibitors; Histone deacetylation; Intrinsic pathway; Macrocycles

Indexed keywords

ANTINEOPLASTIC AGENT; APICIDIN; AZUMAMIDE; CHLAMYDOCIN; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLODEPSIPEPTIDE; CYCLOPEPTIDE; FAS ASSOCIATED DEATH DOMAIN PROTEIN; FR 901375; HISTONE DEACETYLASE INHIBITOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; LARGAZOLE; MACROCYCLIC COMPOUND; ROMIDEPSIN; SPIRUCHOSTATIN A; SPIRUCHOSTATIN B; TETRAPEPTIDE; THAILANDEPSIN; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED DEATH DOMAIN PROTEIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGY; BURKHOLDERIA THAILANDENSIS; CELL PROLIFERATION; CELL STRESS; CHROMATIN CONDENSATION; CHRONIC LYMPHATIC LEUKEMIA; DNA DAMAGE; DNA FRAGMENTATION; DNA REPAIR; DOUBLE STRANDED DNA BREAK; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; G1 PHASE CELL CYCLE CHECKPOINT; G2 PHASE CELL CYCLE CHECKPOINT; HEART ARRHYTHMIA; HISTONE ACETYLATION; HISTONE PHOSPHORYLATION; HUMAN; HYPONATREMIA; INSOMNIA; LIPOPHILICITY; LYMPHOCYTOPENIA; MAXIMUM TOLERATED DOSE; MITOSIS; NAUSEA; NEUTROPENIA; NONHUMAN; OXIDATIVE STRESS; PERIPHERAL T CELL LYMPHOMA; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; QT PROLONGATION; REGULATORY T LYMPHOCYTE; THROMBOCYTOPENIA; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED PERIODIC SYNDROME; VOMITING;

ANTINEOPLASTIC AGENTS; HISTONE DEACETYLASE INHIBITORS; HUMANS; MACROCYCLIC COMPOUNDS; NEOPLASMS; PEPTIDES, CYCLIC;

EID: 84877998693     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867311320140006     Document Type: Article

References (136)

1. Wang, H.; Zhou, W.; Zheng, Z.; Zhang, P.; Tu, B.; He, Q.; Zhu, W.-G. The HDAC inhibitor depsipeptide transactivates the p53/p21 pathway by inducing DNA damage. DNA. Repair, 2012, 11(2), 146-156.
2. Venugopal, B.; Evans, T.R.J. Developing histone deacetylase inhibitors as anti-cancer therapeutics. Curr. Med. Chem., 2011, 18, 1658-1671.
3. Strahl, B.D.; Allis, C.D. The language of covalent histone modifications. Nature, 2000, 403, 41-45. (Pubitemid 30038513)
4. Marmorstein, R.; Roth, S.Y. Histone acetyltransferases: Function, structure, and catalysis. Curr. Opin. Genet. Dev., 2001, 11, 155-161. (Pubitemid 32209199)
5. Haberland, M.; Montgomery, R.L.; Olson, E.N. The many roles of histone deacetylases in development and physiology: Implications for disease and therapy. Nat. Rev. Genet., 2009, 10, 32-42.
6. Martinez-Iglesias, O.; Ruiz-Llorente, L.; Sanchez-Martinez, R.; Garcia, L.; Zambrano, A.; Aranda, A. Histone deacetylase inhibitors: Mechanism of action and therapeutic use in cancer. Clin. Transl. Oncol., 2008, 10, 395-398.
7. Marks, P.A.; Xu, W.S. Histone deacetylase inhibitors: Potential in cancer therapy. J. Cell. Biochem., 2009, 107, 600-608.
8. Mwakwari, S.C.; Patil, V.; Guerrant, W.; Oyelere, A.K. Macrocyclic histone deacetylase inhibitors. Curr. Top. Med. Chem., 2010, 10, 1423-1440.
9. Marks, P.A. The clinical development of histone deacetylase inhibitors as targeted anticancer drugs. Expert. Opin. Investig. Drugs, 2010, 19, 1049-1066.
10. Zhao, Y.; Tan, J.; Zhuang, L.; Jiang, X.; Liu, E.T.; Yu, Q. Inhibitors of histone deacetylases target the Rb-E2F1 pathway for apoptosis induction through activation of proapoptotic protein Bim. Proc. Natl. Acad. Sci. USA, 2005, 102, 16090-16095. (Pubitemid 41552872)
11. Eot-Houllier, G.; Fulcrand, G.; Magnaghi-Jaulin, L.; Jaulin, C. Histone deacetylase inhibitors and genomic instability. Cancer. Lett, 2009, 274, 169-176.
12. Adimoolam, S.; Sirisawad, M.; Chen, J.; Thiemann, P.; Ford, J.M.; Buggy, J.J. HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination. Proc. Natl. Acad. Sci. USA, 2007, 104, 19482-19487.
13. Zhang, Y.; Carr, T.; Dimtchev, A.; Zaer, N.; Dritschilo, A.; Jung, M. Attenuated DNA damage repair by trichostatin A through BRCA1 suppression. Radiat. Res, 2007, 168, 115-124. (Pubitemid 351292932)
14. Bakkenist, C.J.; Kastan, M.B. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature, 2003, 421, 499-506. (Pubitemid 36168436)
15. Petruccelli, L.A.; Dupere-Richer, D.; Pettersson, F.; Retrouvey, H.; Skoulikas, S.; Miller Jr, W.H. Vorinostat induces reactive oxygen species and DNA damage in acute myeloid leukemia cells. PLoS. One 2011, 6, e20987.
16. Rosato, R.R.; Kolla, S.S.; Hock, S.K.; Almenara, J.A.; Patel, A.; Amin, S.; Atadja, P.; Fisher, P.B.; Dent, P.; Grant, S. Histone deacetylase inhibitors activate NF-kappaB in human leukemia cells through an ATM/NEMO-related pathway. J. Biol. Chem, 2010, 285, 10064-10077.
17. Bhalla, S.; Balasubramanian, S.; David, K.; Sirisawad, M.; Buggy, J.; Mauro, L.; Prachand, S.; Miller, R.; Gordon, L.I.; Evens, A.M. PCI-24781 induces caspase and reactive oxygen species-dependent apoptosis through NF-kappaB mechanisms and is synergistic with bortezomib in lymphoma cells. Clin. Cancer. Res, 2009, 15, 3354-3365.
18. Stevens, F.E.; Beamish, H.; Warrener, R.; Gabrielli, B. Histone deacetylase inhibitors induce mitotic slippage. Oncogene, 2008, 27, 1345-1354. (Pubitemid 351317466)
19. Li, Y.; Kao, G.D.; Garcia, B.A.; Shabanowitz, J.; Hunt, D.F.; Qin, J.; Phelan, C.; Lazar M.A. A novel histone deacetylase pathway regulates mitosis by modulating Aurora B kinase activity. Genes. Dev, 2006, 20, 2566-2579. (Pubitemid 44396841)
20. Kerbel, R.S. Tumor angiogenesis. N. Engl. J. Med, 2008, 358, 2039-2049. (Pubitemid 351656458)
21. Kim, S.H.; Jeong, J.W.; Park, J.A.; Lee, J.W.; Seo, J.H.; Jung, B.K.; Bae, M.K.; Kim, K.W. Regulation of the HIF-1alpha stability by histone deacetylases. Oncol. Rep, 2007, 17, 647-651.
22. Dickinson, M.; Johnstone, R.W.; Prince, H.M. Histone deacetylase inhibitors: Potential targets responsible for their anti-cancer effect. Invest. New. Drugs, 2010, 28, Suppl 1: S3-20.
23. Shakespear, M.R.; Halili, M.A.; Irvine, K.M.; Fairlie, D.P.; Sweet, M.J. Histone deacetylases as regulators of inflammation and immunity. Trends. Immunol, 2011, 32,. 335-343.
24. Rikiishi, H. Autophagic and apoptotic effects of HDAC inhibitors on cancer cells. J. Biomed. Biotechnol, 2011, 2011, 830260.
25. Hippert, M.M.; O'Toole, P.S.; Thorburn, A. Autophagy in cancer: Good, bad, or both? Cancer. Res, 2006, 66, 9349-9351.
26. Yue, Z.; Jin, S.; Yang, C.; Levine, A.J.; Heintz, N. Beclin 1, an autophagy gene essential for early embryonic development, is a haploinsufficient tumor suppressor. Proc. Natl. Acad. Sci. USA, 2003, 100, 15077-15082. (Pubitemid 37518019)
27. Joza, N.; Susin, S.A.; Daugas, E.; Stanford, W.L.; Cho, S.K.; Li, C.Y.J.; Sasaki, T.; Elia, A.J.; Mary Cheng, H.Y.; Ravagnan, L.; Ferri, K.F.; Zamzami, N.; Wakeham, A.; Hakem, R.; Yoshida, H.; Kong, Y.Y.; Mak, T.W.; Zuniga-Pflucker, J.C.; Kroemer, G.; Penninger, J.M. Essential role of the mitochondrial apoptosis-inducing factor in programmed cell death. Nature, 2001, 410, 549-554. (Pubitemid 32267191)
28. Fan, T.J.; Han, L.H.; Cong, R.S.; Liang, J. Caspase family proteases and apoptosis. Acta. Biochim. Biophys. Sin, 2005, 37, 719-727. (Pubitemid 44890981)
29. Lavrik, I.N.; Golks, A.; Krammer, P.H. Caspases: Pharmacological manipulation of cell death. J. Clin. Invest., 2005, 115, 2665-2672. (Pubitemid 41434390)
30. Cory, S.; Adams, J.M. The Bcl2 family: Regulators of the cellular life-or-death switch. Nature. Rev. Cancer,. 2002, 2, 647-656. (Pubitemid 37328916)
31. Ashkenazi, A.; Dixit, V.M. Death receptors: Signaling and modulation. Science, 1998, 281, 1305-1308. (Pubitemid 28406815)
32. Peter, M.E.; Krammer, P.H. The CD95(APO-1/Fas) DISC and beyond. Cell. Death. Differ, 2003, 10, 26-35. (Pubitemid 36511830)
33. Micheau, O.; Tschopp, J. Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell, 2003, 114, 181-190. (Pubitemid 36936912)
34. Varfolomeev, E.E.; Ashkenazi, A. Tumor necrosis factor: An apoptosis JuNKie?. Cell,. 2004, 116, 491-497. (Pubitemid 38264427)
35. Sharp, D.A.; Lawrence, D.A.; Ashkenazi, A. Selective knockdown of the long variant of cellular FLICE inhibitory protein augments death receptor-mediated caspase-8 activation and apoptosis. J. Biol. Chem., 2005, 280, 19401-19409. (Pubitemid 41379648)
36. Thome, M.; Tschopp, J. Regulation of lymphocyte proliferation and death by FLIP. Nature. Rev. Immunol., 2001, 1, 50-58. (Pubitemid 33741975)
37. El-Deiry, W.S. Insights into cancer therapeutic design based on p53 and TRAIL receptor signaling. Cell. Death. Differ., 2001, 8, 1066-1075. (Pubitemid 33061824)
38. Eskes, R.; Desagher, S.; Antonsson, B.; Martinou, J.C. Bid induces the oligomerization and insertion of Bax into the outer mitochondrial membrane. Mol. Cell. Biol., 2000, 20, 929-935. (Pubitemid 30044230)
39. Wei, M.C.; Lindsten, T.; Mootha, V.K.; Weiler, S.; Gross, A.; Ashiya, M.; Thompson, C.B.; Korsmeyer, S.J. tBID, a membranetargeted death ligand, oligomerizes BAK to release cytochrome-c. Genes. Dev., 2000, 14, 2060-2071. (Pubitemid 30637355)
40. Green, D.R. Apoptotic pathways: Paper wraps stone blunts scissors. Cell, 2000, 102, 1-4.
41. Jurecekova, J.; Hatok, J.; Stefanikova, A.; Dobrota, D.; Racay, P. Targeting of Bcl-2 family proteins for treatment of acute leukaemia. Gen. Physiol. Biophys., 2011, 30, Spec No: S3-S12.
42. Skommer, J.; Brittain, T.; Raychaudhuri, S. Bcl-2 inhibits apoptosis by increasing the time-to-death and intrinsic cell-to-cell variations in the mitochondrial pathway of cell death. Apoptosis, 2010, 15, 1223-1233.
43. Antignani, A.; Youle, R.J. How do Bax and Bak lead to permeabilization of the outer mitochondrial membrane?. Curr. Opin. Cell. Biol., 2006, 18, 685-689. (Pubitemid 44692478)
44. Croker, B.A.; O'Donnell, J.A.; Nowell, C.J.; Metcalf, D.; Dewson, G.; Campbell, K.J.; Rogers, K.L.; Hu, Y.; Smyth, G.K.; Zhang, J.G.; White, M.; Lackovic, K.; Cengia, L.H.; O'Reilly, L.A.; Bouillet, P.; Cory, S.; Strasser, A.; Roberts, A.W. Fas-mediated neutrophil apoptosis is accelerated by Bid, Bak, and Bax and inhibited by Bcl-2 and Mcl-1. Proc. Natl. Acad. Sci. U. S. A., 2011, 108, 13135-13140.
45. Chinnaiyan, A.M. The apoptosome: Heart and soul of the cell death machine. Neoplasia, 1999, 1, 5-15.
46. Van Loo, G.; Saelens, X.; Van Gurp, M.; MacFarlane, M.; Martin, S.J.; Vandenabeele, P. The role of mitochondrial factors in apoptosis: A Russian roulette with more than one bullet. Cell. Death. Differ., 2002, 9, 1031-1042.
47. Vousden, K.H.; Lu, X. Live or let die: The cell's response to p53. Nature. Rev. Cancer, 2002, 2, 594-604. (Pubitemid 37328926)
48. Boatright, K.M.; Renatus, M.; Scott, F.L.; Sperandio, S.; Shin, H.; Pedersen, I.M.; Ricci, J.E.; Edris, W.A.; Sutherlin, D.P.; Green, D.R.; Salvesen, G.S. A unified model for apical caspase activation. Mol. Cell, 2003, 11, 529-541. (Pubitemid 36293843)
49. Nagata, S. Apoptotic DNA fragmentation. Exp. Cell. Res., 2006, 256, 12-18.
50. Gruenewald, J.; Marahiel, M.A. Chemoenzymatic and templatedirected synthesis of bioactive macrocyclic peptides. Microbiol. Mol. Biol. Rev., 2006, 70(1), 121-146.
51. Furumai, R.; Matsuyama, A.; Kobashi, N.; Lee, K.H.; Nishiyama, M.; Nakajima, H.; Tanaka, A.; Komatsu, Y.; Nishino, N.; Yoshida, M.; Horinouchi, S. FK228 (Depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer. Res., 2002, 62, 4916-4921. (Pubitemid 34984414)
52. Yurek-George, A.; Cecil, A.R.; Mo, A.H.; Wen, S.; Rogers, H.; Habens, F.; Maeda, S.; Yoshida, M.; Packham, G.; Ganesan, A. The first biologically active synthetic analogues of FK228, the depsipeptide histone deacetylase inhibitor. J. Med. Chem., 2007, 50, 5720-5726. (Pubitemid 350106026)
53. Byrd, J.C.; Shinn, C.; Ravi, R.; Willis, C.R.; Waselenko, J.K.; Flinn, I.W.; Dawson, N.A.; Grever, M.R. Depsipep tide (FR901228): A novel therapeutic agent with selective, in. vitro activity against human B-cell chronic lymphocytic leukemia cells. Blood, 1999, 94, 1401-1408. (Pubitemid 29380421)
54. Piekarz, R.L.; Robey, R.W.; Zhan, Z.; Kayastha, G.; Sayah, A.; Abdeldaim, A.H.; Torrico, S.; Bates, S.E. T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: Impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance. Blood,. 2004, 103, 4636-4643. (Pubitemid 38745996)
55. Byrd, J.C.; Marcucci, G.; Parthun, M.R.; Xiao, J.J.; Klisovic, R.B.; Moran, M.; Lin, T.S.; Liu, S.; Sklenar, A.R.; Davis, M.E.; Lucas, D.M.; Fischer, B.; Shank, R.; Tejaswi, S.L.; Binkley, P.; Wright, J.; Chan, K.K; Grever, M.R. A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. Blood, 2005, 105, 959-967. (Pubitemid 40170861)
56. Piekarz, R.L.; Frye, R.; Turner, M.; Wright, J.J.; Allen, S.L.; Kirschbaum, M.H.; Zain, J.; Prince, H.M.; Leonard, J.P.; Geskin, L.J.; Reeder, C.; Joske, D.; Figg, W.D.; Gardner, E.R.; Steinberg, S.M.; Jaffe, E.S.; Stetler-Stevenson, M.; Lade, S.; Fojo, A.T.; Bates, S.E. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J. Clin. Oncol., 2009, 27, 5410-5417.
57. Otterson, G.A.; Hodgson, L.; Pang, H.; Vokes, E.E. Phase II study of the histone deacetylase inhibitor Romidepsin in relapsed small cell lung cancer (Cancer and Leukemia Group B 30304). J. Thorac. Oncol., 2010, 5, 1644-1648.
58. Chen, Y.; Gambs, C.; Abe, Y.; Wentworth, P.Jr.; Janda, K.D. Total synthesis of the depsipeptide FR-901375. J. Org. Chem., 2003, 68, 8902-8905. (Pubitemid 37409537)
59. Greshock, T.J.; Johns, D.M.; Noguchi, Y.; Williams, R.M. Improved total synthesis of the potent HDAC inhibitor FK228 (FR-901228). Org. Lett., 2008, 10(4), 613-616.
60. Vervoort, H.C.; Draskovic, M.; Crews, P. Histone deacetylase inhibitors as a tool to up-regulate new fungal biosynthetic products -isolation of EGM-556, a cyclodepsipeptide, from Microascus. sp. Org. Lett., 2011, 13, 410-413.
61. Bowers, A.A.; Greshock, T.J.; West, N.; Estiu, G.; Schreiber, S.L.; Wiest, O.; Williams, R.M.; Bradner, J.E. Synthesis and conformation-activity relationships of the peptide isosteres of FK228 and Largazole. J. Am. Chem. Soc., 2009, 131, 2900-2905.
62. Ying, Y.; Taori, K.; Kim, H.; Hong, J.; Luesch, H. Total synthesis and molecular target of largazole, a histone deacetylase inhibitor. J. Am. Chem. Soc., 2008, 130, 8455-8459. (Pubitemid 351898566)
63. Li, S.; Yao, H.; Xu, J.; Jiang, S. Synthetic routes and biological evaluation of largazole and its analogues as potent histone deacetylase inhibitors. Molecules, 2011, 16(6), 4681-4694.
64. Bowers, A.A.; West, N.; Newkirk, T.L.; Troutman-Youngman, A.E.; Schreiber, S.L.; Wiest, O.; Bradner, J.E.; Williams, R.M. Synthesis and histone deacetylase inhibitory activity of largazole analogs: Alteration of the zinc-binding domain and macrocyclic scaffold. Org. Lett., 2009, 11(6), 1301-1304.
65. Bhansali, P.; Hanigan, C.L.; Casero Jr., R.A.; Tillekeratne, L.M.V. Largazole and analogues with modified metal-binding motifs targeting histone deacetylases: Synthesis and biological evaluation. J. Med. Chem., 2011, 54(21), 7453-7463.
66. Bowers, A.; West, N.; Taunton, J.; Schreiber, S.L.; Bradner, J.E.; Williams, R.M. Total synthesis and biological mode of action of largazole: A potent class I histone deacetylase inhibitor. J. Am. Chem. Soc., 2008, 130, 11219-11222.
67. Ying, Y.; Liu, Y.; Byeon, S.R.; Kim, H.; Luesch, H.; Hong, J. Synthesis and activity of largazole analogues with linker and macrocycle modification. Org. Lett., 2008, 10(18), 4021-4024.
68. Wang, B.; Huang, P.H.; Chen, C.S.; Forsyth, C.J. Total syntheses of the histone deacetylase inhibitors largazole and 2-epi-largazole: Application of N-heterocyclic carbene mediated acylations in complex molecule synthesis. J. Org. Chem., 2011, 76, 1140-1150.
69. Cole, K.E.; Dowling, D.P.; Boone, M.A.; Phillips, A.J.; Christianson, D.W. Structural basis of the antiproliferative activity of largazole, a depsipeptide inhibitor of the histone deacetylases. J. Am. Chem. Soc., 2011, 133, 12474-12477.
70. Hong, J.; Luesch, H. Largazole: From discovery to broadspectrum therapy. Nat. Prod. Rep., 2012, 29(4), 449-456.
71. Liu, Y.; Salvador, L.A.; Byeon, S.; Ying, Y.; Kwan, J.C.; Law, B.K.; Hong, J.; Luesch, H. Anticolon cancer activity of largazole, a marine-derived tunable histone deacetylase inhibitor. The. J. Pharmacol. Exp. Ther., 2010, 335(2), 351-361.
72. Tashiro, E.; Tsuchiya, A.; Imoto, M. Functions of cyclin D1 as an oncogene and regulation of cyclin D1 expression. Cancer. Sci,. 2007, 98, 629-635. (Pubitemid 46563437)
73. Taori, K.; Liu, Y.; Paul, V.J.; Luesch, H. Combinatorial strategies by marine cyanobacteria: Symplostatin 4, an antimitotic natural dolastatin 10/15 hybrid that synergizes with the coproduced HDAC inhibitor largazole. Chembiochem., 2009, 10(10), 1634-1639.
74. Benelkebir, H.; Marie, S.; Hayden, A.L.; Lyle, J.; Loadman, P.M.; Crabb, S.J.; Packham, G.; Ganesan, A. Total synthesis of largazole and analogues: HDAC inhibition, antiproliferative activity and metabolic stability. Bioorg. Med. Chem., 2011, 19, 3650-3658.
75. Masuoka, Y.; Nagai, A.; Shin-ya, K.; Furihata, K.; Nagai, K.; Suzuki, K.; Hayakawa, Y.; Seto, H. Spiruchostatins A and B, novel gene expression-enhancing substances produced by Pseudomonas. sp. Tetrahedron. Lett., 2001, 42(1), 41-44. (Pubitemid 32011701)
76. Yurek-George, A.; Habens, F.; Brimmell, M.; Packham, G.; Ganesan, A. Total synthesis of spiruchostatin A, a potent histone deacetylase inhibitor. J. Am. Chem. Soc., 2004, 126, 1030-1031. (Pubitemid 38140727)
77. Davies, E.R.; Haitchi, H.M.; Thatcher, T.H.; Sime, P.J.; Kottmann, R.M.; Ganesan, A.; Packham, G.; O'Reilly, K.M.; Davies, D.E. Spiruchostatin A inhibits proliferation and differentiation of fibroblasts from patients with pulmonary fibrosis. Am. J. Respir. Cell. Mol. Biol., 2012, 46(5), 687-694.
78. Crabb, S.J.; Howell, M.; Rogers, H.; Ishfaq, M.; Yurek-George, A.; Carey, K.; Pickering, B.M.; East, P.; Mitter, R.; Maeda, S.; Johnson, P.W.M.; Townsend, P.; Shin-ya, K.; Yoshida, M.; Ganesan, A.; Packham, G. Characterisation of the in. vitro activity of the depsipeptide histone deacetylase inhibitor spiruchostatin A. Biochem. Pharmacol., 2008, 76, 463-475.
79. Munster, P.N.; Troso-Sandoval, T.; Rosen, N.; Rifkind, R.; Marks, P.A.; Richon, V.M. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells. Cancer. Res., 2001, 61, 8492-8497. (Pubitemid 33131130)
80. Kanno, S.-I.; Maeda, N.; Tomizawa, A.; Yomogida, S.; Katoh, T.; Ishikawa, M. Involvement of p21waf1/cip1 expression in the cytotoxicity of the potent histone deacetylase inhibitor spiruchostatin B towards susceptible NALM-6 human B cell leukemia cells. Int. J. Oncol., 2012, 40, 1391-1396.
81. Lijima, Y.; Munakata, A.; Shinya, K.; Ganesan, A.; Doi, T.; Takahashi, T. A solid-phase total synthesis of the cyclic depsipeptide HDAC inhibitor spiruchostatin A. Tetrahedron. Lett., 2009, 50, 2970-2972.
82. Calandra, N.A.; Cheng, Y.L.; Kocak, K.A.; Miller, J.S. Total synthesis of spiruchostatin A via chemoselective macrocyclization using an accessible enantiomerically pure latent thioester. Org. Lett., 2009, 11(9), 1971-1974.
83. Fuse, S.; Okada, K.; Iijima, Y.; Munakata, A.; Machida, K.; Takahashi, T.; Takagi, M.; Shin-yad, K.; Doi, T. Total synthesis of spiruchostatin B aided by an automated synthesizer. Org. Biomol. Chem., 2011, 9, 3825-3833.
84. Narita, K.; Kikuchi, T.; Watanabe, K.; Takizawa, T.; Oguchi, T.; Kudo, K.; Matsuhara, K.; Abe, H.; Yamori, T.; Yoshida, M.; Katoh, T. Total synthesis of the bicyclic depsipeptide HDAC inhibitors spiruchostatins A and B, 5''-epi-spiruchostatin B, FK228 (FR901228) and preliminary evaluation of their biological activity. Chemistry, 2009, 15(42), 11174-11186.
85. Klausmeyer, P.; Shipley, S.M.; Zuck, K.M.; McCloud, T.G. Histone deacetylase inhibitors from Burkholderia. thailandensis. J. Nat. Prod., 2011, 74, 2039-2044.
86. Wang, C.; Henkes, L.M.; Doughty, L.B.; He, M.; Wang, D.; Meyer-Almes, F.-J.; Cheng, Y.-Q. Thailandepsins: Bacterial products with potent histone deacetylase inhibitory activities and broadspectrum antiproliferative activities. J. Nat. Prod., 2011, 74, 2031-2038.
87. Biggins, J.B.; Gleber, C.D.; Brady, S.F. Acyldepsipeptide HDAC inhibitor production induced in Burkholderia. thailandensis. Org. Lett.,. 2011, 13(6), 1536-1539.
88. Benelkebir, H.; Donlevy, A.M.; Packham, G.; Ganesan, A. Total synthesis and stereochemical assignment of burkholdac B, a depsipeptide HDAC inhibitor. Org. Lett.,. 2011, 13(24), 6334-6337.
89. Meinke, P.T.; Liberator, P. Histone deacetylase: A target for antiproliferative and antiprotozoal agents. Curr. Med. Chem., 2001, 8(2), 211-235. (Pubitemid 32416448)
90. Shute, R.E.; Kawai, M.; Rich, D.H. Conformationally constrained biologically active peptides: Tentative identification of the antimi togenic bioactive confomer of the naturally occurring cyclic tetrapeptides. Tetrahedron, 1988, 44(3), 685-695. (Pubitemid 18051776)
91. Horne, W.S.; Olsen, C.A.; Beierle, J.M.; Montero, A.; Ghadiri, M.R. Probing the bioactive conformation of an archetypal natural product HDAC inhibitor with conformationally homogeneous triazole-modified cyclic tetrapeptides. Angew. Chem. Int. Ed. Engl., 2009, 48, 4718-4724.
92. Huang, D.; Li, X.; Sun, L.; Xiu, Z.; Nishino, N. Synthesis, evaluation and molecular modeling of cyclic tetrapeptide histone deacetylase inhibitors as anticancer agents. J. Pept. Sci., 2012, 18(4), 242-251.
93. Chatterjee, J.; Gilon, C.; Hoffman, A.; Kessler, H. N-Methylation of peptides: A new perspective in medicinal chemistry. Acc. Chem. Res.,. 2008, 41(10), 1331-1342.
94. Tamamura, H.; Araki, T.; Ueda, S.; Wang, Z.; Oishi, S.; Esaka, A.; Trent, J.O.; Nakashima, H.; Yamamoto, N.; Peiper, S.C.; Otaka, A.; Fujii, N. Identification of novel low molecular weight CXCR4 antagonists by structural tuning of cyclic tetrapeptide scaffolds. J. Med. Chem., 2005, 48, 3280-3289. (Pubitemid 40628048)
95. Glenn, M.P.; Kelso, M.J.; Tyndall, J.D.A.; Fairlie, D.P. Conformationally homogeneous cyclic tetrapeptides: Useful new threedimensional scaffolds. J. Am. Chem. Soc., 2003, 125(3), 640-641. (Pubitemid 36109919)
96. Norgren, A.S.; Buettner, F.; Prabpai, S.; Kongsaeree, P.; Arvidsson, P.I. Beta2-amino acids in the design of conformationally homogeneous cyclo-peptide scaffolds. J. Org. Chem., 2006, 71(18), 6814-6821. (Pubitemid 44645656)
97. Singh, S.B.; Zink, D.L.; Polishook, J.D.; Dombrowski, A.W.; Darkin-Rattray, S.J.; Schmatz, D.M.; Goetz, M.A. Apicidins: Novel cyclic tetrapeptides as coccidiostats and antimalarial agents from Fusarium. pallidoroseum. Tetrahedron. Lett., 1996, 37, 8077-8080. (Pubitemid 26366232)
98. Darkin-Rattray, S.J.; Gurnett, A.M.; Myers, R.W.; Dulski, P.M.; Crumley, T.M.; Allocco, J.J.; Cannova, C.; Meinke, P.T.; Colletti, S.L.; Bednarik, M.A.; Singh, S.B.; Goetz, M.A.; Dombrowski, A.W.; Polishook, J.D.; Schmatz, D.M. Apicidin: A novel antiprotozoal agent that inhibits parasite histone deacetylase. Proc. Natl. Acad. Sci. U.S.A., 1996, 93, 13143-13147. (Pubitemid 26382783)
99. Ueda, T.; Takai, N.; Nishida, M.; Nasu, K.; Narahara, H. Apicidin, a novel histone deacetylase inhibitor, has profound anti-growth activity in human endometrial and ovarian cancer cells. Int. J. Mol. Med., 2007, 19, 301-308.
100. Han, J.W.; Ahn, S.H.; Park, S.H.; Wang, S.Y.; Bae, G.-U.; Seo, D.-W.; Kwon, H.-K.; Hong, S.; Lee, H.Y.; Lee, Y.W.; Lee, H.-W. Apicidin, a histone deacetylase inhibitor, inhibits proliferation of tumor cells via induction of p21WAF1/Cip1 and gelsolin. Cancer. Res., 2000, 60, 6068-6074.
101. Cheong, J.-W.; Chong, S.Y.; Kim, J.Y.; Eom, J.I.; Jeung, H.K.; Maeng, H.Y.; Lee, S.T.; Min, Y.H. Induction of apoptosis by apicidin, a histone deacetylase inhibitor, via the activation of mitochondria-dependent caspase cascades in human Bcr-Abl-positive leukemia cells. Clin. Cancer. Res., 2003, 9, 5018-5027. (Pubitemid 37323309)
102. Kim, J.S.; Jeung, H.K.; Cheong, J.-W.; Maeng, H.; Lee, S.T.; Hahn, J.S.; Ko, Y.W.; Min, Y.H. Apicidin potentiates the imatinibinduced apoptosis of Bcr-Abl-positive human leukaemia cells by enhancing the activation of mitochondria-dependent caspase cascades. British. J. Haematol., 2003, 124, 166-178.
103. Singh, S.B.; Zink, D.L.; Liesch, J.M.; Mosley, R.T.; Dombrowski, A.W.; Bills, G.F. Structure and chemistry of apicidins, a class of novel cyclic tetrapeptides without a terminal ?-keto epoxide as inhibitors of histone deacetylase with potent antiprotozoal activities. J. Org. Chem., 2002, 67, 815-825. (Pubitemid 34135683)
104. Colletti, S.L.; Myers, R.W.; Darkin-Rattray, S.J.; Gurnett, A.M.; Dulski, P.M.; Galuska, S.; Allocco, J.J.; Ayer, M.B.; Li, C.; Lim, J.; Crumley, T.M.; Cannova, C.; Schmatz, D.M.; Wyvratt, M.J.; Fisher, M.H.; Meinke, P.T. Broad spectrum antiprotozoal agents that inhibit histone deacetylase: Structure-activity relationships of apicidin. Part 1. Bioorg. Med. Chem. Lett., 2001, 11, 107-111. (Pubitemid 32099620)
105. Meinke, P.T.; Colletti, S.L.; Doss, G.; Myers, R.W.; Gurnett, A.M.; Dulski, P.M.; Darkin-Rattray, S.J.; Allocco, J.J.; Galuska, S.; Schmatz, D.M.; Wyvratt, M.J.; Fisher, M.H. Synthesis of apicidinderived quinolone derivatives: Parasite-selective histone deacetylase inhibitors and antiproliferative agents. J. Med. Chem., 2000, 43, 4919-4922. (Pubitemid 32002704)
106. Nakao, Y.; Yoshida, S.; Matsunaga, S.; Shindoh, N.; Terada, Y.; Nagai, K.; Yamashita, J.K.; Ganesan, A.; Van Soest, R.W.M.; Fusetani, N. Azumamides A-E: Histone deacetylase inhibitory cyclic tetrapeptides from the marine sponge Mycale. izuensis. Angew. Chem. Int. Ed., 2006, 45, 7553-7557. (Pubitemid 44851680)
107. Maulucci, N.; Chini, M.G.; Di Micco, S.; Izzo, I.; Cafaro, E.; Russo, A.; Gallinari, P.; Paolini, C.; Nardi, M.C.; Casapullo, A.; Riccio, R.; Bifulco, G.; De Riccardis, F. Molecular insights into azumamide E histone deacetylases inhibitory activity. J. Am. Chem. Soc., 2007, 129, 3007-3012. (Pubitemid 46417978)
108. Wen, S.; Carey, K.L.; Nakao, Y.; Fusetani, N.; Packham, G.; Ganesan, A. Total synthesis of azumamide A and azumamide E, evaluation as histone deacetylase inhibitors, and design of a more potent analogue. Org. Lett., 2007, 9, 1105-1108.
109. Chandrasekhar, S.; Rao, C.L.; Seenaiah, M.; Naresh, P.; Jagadeesh, B.; Manjeera, D.; Sarkar, A.; Bhadra M.P. Total synthesis of Azumamide E and sugar amino acid-containing analogue. J. Org. Chem., 2009, 74, 401-404.
110. Nakao, Y.; Narazaki, G.; Hoshino, T.; Maeda, S.; Yoshida, M.; Maejima, H.; Yamashita, J.K. Evaluation of antiangiogenic activity of azumamides by the in. vitro vascular organization model using mouse induced pluripotent stem (iPS) cells. Bioorg. Med. Chem. Lett., 2008, 18, 2982-2984. (Pubitemid 351608862)
111. Islam, M.S.; Bhuiyan, M.P.; Islam, M.N.; Nsiama, T.K.; Oishi, N.; Kato, T.; Nishino, N.; Ito, A.; Yoshida, M. Evaluation of functional groups on amino acids in cyclic tetrapeptides in histone deacetylase inhibition. Amino. Acids, 2012, 42(6), 2103-2110.
112. Nishino, N.; Jose, B.; Shinta, R.; Kato, T.; Komatsub, Y.; Yoshida M. Chlamydocin-hydroxamic acid analogues as histone deacetylase inhibitors. Bioorg. Med. Chem.,. 2004, 12, 5777-5784. (Pubitemid 39388176)
113. Bhuiyan, M.P.I.; Kato, T.; Okauchi, T.; Nishino, N.; Maeda, S.; Nishino, T.G.; Yoshida, M. Chlamydocin analogs bearing carbonyl group as possible ligand toward zinc atom in histone deacetylases. Bioorg. Med. Chem., 2006, 14, 3438-3446.
114. Closse, A.; Huguenin, R. Isolation and structural clarification of chlamydocin. Helv. Chim. Acta., 1974, 57, 533-545.
115. Shivashimpi, G.M.; Amagai, S.; Kato, T.; Nishino, N.; Maeda, S.; Nishino, T.G.; Yoshida, M. Molecular design of histone deacetylase inhibitors by aromatic ring shifting in chlamydocin framework. Bioorg. Med. Chem.,. 2007, 15, 7830-7839. (Pubitemid 47575905)
116. Nishino, N.; Shivashimpi, G.M.; Soni, P.B.; Bhuiyan, M.P.I.; Kato, T.; Maeda, S.; Nishino, T.G.; Yoshida, M. Interaction of aliphatic cap group in inhibition of histone deacetylases by cyclic tetrapeptides. Bioorg. Med. Chem., 2008, 16, 437-445.
117. De Schepper, S.; Bruwiere, H.; Verhulst, T.; Steller, U.; Andries, L.; Wouters, W.; Janicot, M.; Arts, J.; Van Heusden, J. Inhibition of histone deacetylases by chlamydocin induces apoptosis and proteasome-mediated degradation of survivin. J. Pharmacol. Exp. Ther.,. 2003, 304(2), 881-888. (Pubitemid 36152369)
118. Komatsu, Y.; Tomizaki, K.; Tsukamoto, M.; Kato, T.; Nishino, N.; Sato, S.; Yamori, T.; Tsuruo, T.; Furumai, R.; Yoshida, M.; Horinouchi, S.; Hayashi, H. Cyclic hydroxamic acid-containing peptide 31, a potent synthetic histone deacetylase inhibitor with antitumor activity. Cancer. Res., 2001, 61, 4459-4466. (Pubitemid 32685775)
119. Heltweg, B.; Dequiedt, F.; Marshall, B.L.; Brauch, C.; Yoshida, M.; Nishino, N.; Verdin, E.; Jung, M. Subtype selective substrates for histone deacetylases. J. Med. Chem., 2004, 47, 5235-5243. (Pubitemid 39314921)
120. Furumai, R.; Komatsu, Y.; Nishino, N.; Khochbin, S.; Yoshida, M.; Horinouchi, S. Potent histone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptide antibiotics including trapoxin. Proc. Natl. Acad. Sci. USA., 2001, 98, 87-92. (Pubitemid 32095868)
121. Murakami, K.; Matsubara, H.; Hoshino, I.; Akutsu, Y.; Miyazawa, Y.; Matsushita, K.; Sakata, H.; Nishimori, T.; Usui, A.; Kano, M.; Nishino, N.; Yoshida, M. CHAP31 induces apoptosis only via the intrinsic pathway in human esophageal cancer cells. Oncol., 2010, 78(1), 62-74.
122. Taura, K.; Yamamoto, Y.; Nakajima, A.; Hata, K.; Uchinami, H.; Yonezawa, K.; Hatano, E.; Nishino, N.; Yamaoka, Y. Impact of novel histone deacetylase inhibitors, CHAP31 and FR901228 (FK228), on adenovirus-mediated transgene expression. J. Gene. Med., 2004, 6(5), 526-536. (Pubitemid 40228068)
123. Kano, M.; Yamada, S.; Hoshino, I.; Murakami, K.; Akutsu, Y.; Sakata, H.; Nishimori, T.; Usui, A.; Miyazawa, Y.; Kamada, T.; Tsujii, H.; Matsubara, H. Effects of carbon-ion radiotherapy combined with a novel histone deacetylase inhibitor, cyclic hydroxamic-acid-containing peptide 31 in human esophageal squamous cell carcinoma. Anticancer. Res., 2009, 29, 4433-4438.
124. Jose, B.; Okamura, S.; Kato, T.; Nishino, N.; Sumida, Y.; Yoshida, M. Toward an HDAC6 inhibitor: Synthesis and conformational analysis of cyclic hexapeptide hydroxamic acid designed from ?-tubulin sequence. Bioorg. Med. Chem., 2004, 12, 1351-1356. (Pubitemid 38296525)
125. Islam, N.M.; Kato, T.; Nishino, N.; Kim, H.-J.; Ito, A.; Yoshida, M. Bicyclic peptides as potent inhibitors of histone deacetylases: Optimization of alkyl loop length. Bioorg. Med. Chem. Lett., 2010, 20, 997-999.
126. Hoque, M.A.; Arai, T.; Nishino, N.; Kim, H.-J.; Ito, A.; Yoshida, M. Cyclic tetrapeptides with thioacetate tails or intramolecular disulfide bridge as potent inhibitors of histone deacetylases. Bioorg. Med. Chem. Lett., 2012,. 10.1016/j.bmcl.2012.03.004.
127. Terracciano, S,; Micco, S.D.; Bifulco, G.; Gallinari, P.; Riccio, R.; Bruno, I. Synthesis and biological activity of cyclotetrapeptide analogues of the natural HDAC inhibitor FR235222. Bioorg. Med. Chem., 2010, 18, 3252-3260.
128. Singh, E.K.; Ravula, S.; Pan, C.-M.; Pan, P.-S.; Vasko, R.C.; Lapera, S.A.; Weerasinghe, S.V.W.; Pflum, M.K.H.; McAlpine, S.R. Synthesis and biological evaluation of histone deacetylase inhibitors that are based on FR235222: A cyclic tetrapeptide scaffold. Bioorg. Med. Chem. Lett., 2008, 18, 2549-2554. (Pubitemid 351503893)
129. Hu, F.; Chou, C.J.; Gottesfeld, J.M. Design and synthesis of novel hybrid benzamide-peptide histone deacetylase inhibitors. Bioorg. Med. Chem. Lett., 2009, 19, 3928-3931.
130. Montero, A.; Beierle, J.M.; Olsen, C.A.; Ghadiri, M.R. Design, synthesis, biological evaluation, and structural characterization of potent histone deacetylase inhibitors based on cyclic ?/?-tetrapeptide architectures. J. Am. Chem. Soc.,. 2009, 131, 3033-3041.
131. Auzzas, L.; Larsson, A.; Matera, R.; Baraldi, A.; Deschenes-Simard, B.; Giannini, G.; Cabri, W.; Battistuzzi, G.; Gallo, G.; Ciacci, A.; Vesci, L.; Pisano, C.; Hanessian, S. Non-natural macrocyclic inhibitors of histone deacetylases: Design, synthesis, and activity. J. Med. Chem., 2010, 53(23), 8387-8399.
132. Olsen, C.A.; Ghadiri, M.R. Discovery of potent and selective histone deacetylase inhibitors via focused combinatorial libraries of cyclic ?3?-tetrapeptides. J. Med. Chem., 2009, 52(23), 7836-7846.
133. Marsault, E.; Peterson, M.L. Macrocycles are great cycles: Applications, opportunities, and challenges of synthetic macrocycles in drug discovery. J. Med. Chem., 2011, 54, 1961-2004.
134. Singh, E.K.; Nazarova, L.A.; Lapera, S.A.; Alexander, L.D.; McAlpine, S.R. Histone deacetylase inhibitors: Synthesis of cyclic tetrapeptides and their triazole analogues. Tetrahedron. Lett., 2010, 51(33), 4357-4360.
135. Nishino, N.; Jose, B.; Okamura, S.; Ebisusaki, S.; Kato, T.; Sumida, Y.; Yoshida, M. Cyclic tetrapeptides bearing a sulfhydryl group potently inhibit histone deacetylases. Org. Lett., 2003, 5(26), 5079-5082. (Pubitemid 38073003)
136. Ai, T.; Cui, H.; Chen, L. Multi-targeted histone. deacetylase inhibitors in cancer therapy. Curr. Med. Chem., 2012, 19, 475-487.